Trial Profile
A multinational, randomized, double-blind study comparing aflibercept versus placebo in patients treated with second-line docetaxel after failure of one platinum based therapy for locally advanced or metastatic non-small-cell lung cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms VITAL
- Sponsors Sanofi
- 10 Sep 2012 Results published in the Journal of Clinical Oncology.
- 03 Mar 2012 Planned number of patients changed from 900 to 910 as reported by European Clinical Trials Database.
- 05 Jan 2012 Actual end date Oct 2011 added as reported by ClinicalTrials.gov.